Andrea Sboner

researcher

Andrea Sboner is …
instance of (P31):
humanQ5

External links are
P11507IRIS FBK author ID00345
P11506IRIS UNITN author ID00449
P496ORCID iD0000-0001-6915-3070
P3829Publons author ID304603
P1053ResearcherIDC-6487-2008
P1153Scopus author ID55884911800

P735given nameAndreaQ493293
AndreaQ493293
P106occupationresearcherQ1650915
P21sex or gendermaleQ6581097

Reverse relations

author (P50)
Q91554114A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Q39637398A multiple classifier system for early melanoma diagnosis.
Q39721477An automated procedure to properly handle digital images in large scale tissue microarray experiments.
Q57693440Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer
Q57314640Automatic model selection in cost-sensitive boosting
Q95601997Building an International Consortium for Tracking Coronavirus Health Status
Q96128119Building an international consortium for tracking coronavirus health status
Q39688600Clinical validation of an automated system for supporting the early diagnosis of melanoma.
Q41315076Clonal evolution of chemotherapy-resistant urothelial carcinoma.
Q33610866Comparison and calibration of transcriptome data from RNA-Seq and tiling arrays
Q64073046Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Q34452282Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing
Q37173727Distinct genomic aberrations associated with ERG rearranged prostate cancer
Q38768101Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Q27939657Diverse protein kinase interactions identified by protein microarrays reveal novel connections between cellular processes
Q36730577Epigenomic alterations in localized and advanced prostate cancer
Q34775924Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
Q27499410FusionSeq: a modular framework for finding gene fusions by analyzing Paired-End RNA-Sequencing data
Q112713263G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer
Q21144925Genomic analysis of the hydrocarbon-producing, cellulolytic, endophytic fungus Ascocoryne sarcoides
Q28254700Genomics and privacy: implications of the new reality of closed data for the field
Q34125015IQSeq: integrated isoform quantification analysis based on next-generation sequencing
Q34212750Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma
Q57693316Identifying an ERG-positive Subclass with Clinical Progression Using Expression Profiling
Q112642696Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer
Q28301622Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project
Q22065599Integrative annotation of variants from 1092 humans: application to cancer genomics
Q27853170Integrative clinical genomics of advanced prostate cancer
Q46920853Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer
Q39385550Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets
Q33541296Molecular sampling of prostate cancer: a dilemma for predicting disease progression
Q28771715N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Q24647034N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer
Q41867966Novel MIR143-NOTCH fusions in benign and malignant glomus tumors
Q33874474Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma
Q112713949Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer
Q34545103Organoid cultures derived from patients with advanced prostate cancer
Q55367999Patient derived organoids to model rare prostate cancer phenotypes.
Q38885294Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Q96766154Publisher Correction: Building an international consortium for tracking coronavirus health status
Q92451836Publisher Correction: The long tail of oncogenic drivers in prostate cancer
Q36950514Punctuated evolution of prostate cancer genomes
Q33764103RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries
Q50943467Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456.
Q37072709Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma
Q84688558Robust-linear-model normalization to reduce technical variability in functional protein microarrays
Q101216831Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
Q90008246SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy
Q51099413SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Q47333876SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Q36210354SPOP mutation leads to genomic instability in prostate cancer.
Q37584305SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Q24617949The genomic complexity of primary human prostate cancer
Q52611753The long tail of oncogenic drivers in prostate cancer.
Q35632563The real cost of sequencing: higher than you think!
Q42924615The role of disorder in interaction networks: a structural analysis
Q30587156Unraveling the clonal hierarchy of somatic genomic aberrations.
Q36186603VAT: a computational framework to functionally annotate variants in personal genomes within a cloud-computing environment

Search more.